Blood Res.  2023 Dec;58(4):240-242. 10.5045/br.2023.2023169.

Clinico-pathological features and treatment outcomes of high-grade B cell lymphoma—a tertiary cancer center experience

• Mukherjee A
• Rainchwar S
• Singh A
• Halder R
• Patra PC
• Ahmed R
• Bhurani D
• Agrawal N

• KMID: 2550207
• DOI: http://doi.org/10.5045/br.2023.2023169

Reference

1. Chen BJ, Fend F, Campo E, Quintanilla-Martinez L. 2019; Aggressive B-cell lymphomas-from morphology to molecular pathogenesis. Ann Lymphoma. 3:1–22. DOI: 10.21037/aol.2018.12.02.

2. Swerdlow SH, Campo E, Pileri SA, et al. 2016; The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127:2375–90. DOI: 10.1182/blood-2016-01-643569. PMID: 26980727. PMCID: PMC4874220.

3. Perry AM, Crockett D, Dave BJ, et al. 2013; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol. 162:40–9. DOI: 10.1111/bjh.12343. PMID: 23600716.

4. Moharana L, Dasappa L, Babu S, et al. 2022; Comparison between CHOP and DAEPOCH with or without rituximab in adult high grade B cell lymphoma, not otherwise specified; a retrospective study from a tertiary cancer hospital in South India. Indian J Hematol Blood Transfus. 38:15–23. DOI: 10.1007/s12288-021-01427-8. PMID: 35125708. PMCID: PMC8804013.

5. Karunakaran P, Selvarajan G, Kalaiyarasi JP, et al. 2022; Therapeutic outcomes in high-grade B-cell lymphoma, NOS: retrospective analysis. South Asian J Cancer. 11:68–72. DOI: 10.1055/s-0041-1739365. PMID: 35833044. PMCID: PMC9273314. PMID: 64de450a1bbd433aa5769b7566be1ed5.